Ivabradine prevents doxorubicin-induced cardiotoxicity via attenuating mitochondrial dysfunction and mitochondrial dynamic imbalance in H9C2 cells and rats

31 August 2024 (15:00 - 15:30)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Adivitch Sripusanapan

Chiang Mai University, Chiang Mai (Thailand)

4 More presentations in this session

Presentation thumbnail

Is there an association of anthracyclines with HFrEF and/or HFpEF in patients treated for breast cancer or lymphoma after 30 years of follow-up? Insights from the Rochester epidemiology project

Doctor E. Tellez Garcia (Rochester, US)

Abstract Slides Video

Presentation thumbnail

A new heart transplant resource: DBD donor with out-of-hospital cardiac arrest

Doctor G. Fischetti (Bari, IT)

Abstract Slides Video

Presentation thumbnail

Circulating metabolites in patients with chronic heart failure are related to increased lipid utilisation but not to gut microbiota alterations

Doctor A. Nendl (Oslo, NO)

Abstract Slides Video

Presentation thumbnail

Adipose tissue/ heart lipid transport determines cardiac diastolic function

Mr G. Trimarchi (Berlin, DE)

Abstract Slides Video

Access the full session

Session thumbnail

Miscellaneous clinical studies in heart failure (3)

The Event

Event poster

ESC Congress 2024

31 August 2024 15:00 CET

You may be interested in

Congress Presentation

Chalcone-enriched fraction protects against chemotherapy-induced cardiotoxicity by restoring mitochondrial function and reducing oxidative stress

Congress Session

Cardiotoxicity of cancer therapies

Congress Presentation

Targeting mitochondrial dysfunction with the exercise-derived metabolite beta-aminoisobutyric acid protects against doxorubicin-induced cardiomyopathy

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources